Last update 21 Nov 2024

Clade C and Mosaic gp140 HIV bivalent vaccine(Janssen Vaccines & Prevention)

Overview

Basic Info

Drug Type
Prophylactic vaccine
Synonyms-
Target
gp140
Mechanism
gp140 inhibitors(HIV gp140 inhibitors)
Therapeutic Areas
Immune System DiseasesInfectious DiseasesUrogenital Diseases
Active Indication
HIV Infections
Inactive Indication-
Originator Organization
Janssen Vaccines & Prevention BV
Active Organization
Janssen Vaccines & Prevention BV
Inactive Organization-
Drug Highest PhasePhase 3
First Approval Date-
Regulation-
Login to view timeline

Related

1
Clinical Trials associated with Clade C and Mosaic gp140 HIV bivalent vaccine(Janssen Vaccines & Prevention)
NCT03964415 / CompletedPhase 3
A Multi-center, Randomized, Double-blind, Placebo-controlled Phase 3 Efficacy Study of a Heterologous Vaccine Regimen of Ad26.Mos4.HIV and Adjuvanted Clade C gp140 and Mosaic gp140 to Prevent HIV-1 Infection Among Cis-gender Men and Transgender Individuals Who Have Sex With Cis-gender Men and/or Transgender Individuals
100 Clinical Results associated with Clade C and Mosaic gp140 HIV bivalent vaccine(Janssen Vaccines & Prevention)
Login to view more data
100 Translational Medicine associated with Clade C and Mosaic gp140 HIV bivalent vaccine(Janssen Vaccines & Prevention)
Login to view more data
100 Patents (Medical) associated with Clade C and Mosaic gp140 HIV bivalent vaccine(Janssen Vaccines & Prevention)
Login to view more data
100 Deals associated with Clade C and Mosaic gp140 HIV bivalent vaccine(Janssen Vaccines & Prevention)
Login to view more data

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
HIV InfectionsPhase 3
AR
Janssen Vaccines & Prevention BV
31 Oct 2019
HIV InfectionsPhase 3
BR
Janssen Vaccines & Prevention BV
31 Oct 2019
HIV InfectionsPhase 3
PL
Janssen Vaccines & Prevention BV
31 Oct 2019
HIV InfectionsPhase 3
PR
Janssen Vaccines & Prevention BV
31 Oct 2019
HIV InfectionsPhase 3
PE
Janssen Vaccines & Prevention BV
31 Oct 2019
HIV InfectionsPhase 3
ES
Janssen Vaccines & Prevention BV
31 Oct 2019
HIV InfectionsPhase 3
MX
Janssen Vaccines & Prevention BV
31 Oct 2019
HIV InfectionsPhase 3
IT
Janssen Vaccines & Prevention BV
31 Oct 2019
HIV InfectionsPhase 3
US
Janssen Vaccines & Prevention BV
31 Oct 2019
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date

No Data

Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
login
or
view full example data
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
login
or
view full example data
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
login
or
view full example data
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
login
or
view full example data
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
login
or
view full example data
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
login
or
view full example data
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free